KR880012217A - 캘콘 유도체를 사용한 종량 조직의 증식 억제방법 - Google Patents

캘콘 유도체를 사용한 종량 조직의 증식 억제방법 Download PDF

Info

Publication number
KR880012217A
KR880012217A KR1019880003946A KR880003946A KR880012217A KR 880012217 A KR880012217 A KR 880012217A KR 1019880003946 A KR1019880003946 A KR 1019880003946A KR 880003946 A KR880003946 A KR 880003946A KR 880012217 A KR880012217 A KR 880012217A
Authority
KR
South Korea
Prior art keywords
group
dimethoxyphenyl
alkyl
proliferation
trimethoxyphenyl
Prior art date
Application number
KR1019880003946A
Other languages
English (en)
Inventor
엘. 에드워드 마이클
엠. 스테머릭 데이비드
피이. 선카라 세이
Original Assignee
개리 디. 스트리트
메렐 다우 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 개리 디. 스트리트, 메렐 다우 파마슈티칼스 인코포레이티드 filed Critical 개리 디. 스트리트
Publication of KR880012217A publication Critical patent/KR880012217A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

캘콘 유도체를 사용한 종량 조직의 증식 억제방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 유효량의 일반식(1)의 캘콘유도체 또는 그의 약제학적으로 허용되는 염을 투여함을 특징으로 하여, 그를 필요로 하는 환자에 있어서 미소관을 형성하는 튜불린의 중합화를 억제하는 방법.
    상기 식에서, Ar은 2,5-디메톡시페닐, 2,3,4-트리메톡시페닐, 또는 3,4,5-트리메톡시페닐그룹이고 ; R1은 수소, (C1-C4)알킬, 클로로 또는 브로모그룹이며 ; R2는 -N(R)2또는 -NH(O)R (여기서, R은 (C1-C4)알킬그룹이다)이다.
  2. 제 1 항에 있어서, R1이 (C1-C4)알킬그룹인 방법.
  3. 제 1 항에 있어서, R1이 메틸그룹인 방법.
  4. 제1,2 또는 3항에 있어서, R2가 -N(R)2인 방법.
  5. 제 4 항에 있어서, R이 메틸그룹인 방법.
  6. 제 1 항 내지 제 5 항중 어느 한 항에 있어서, Ar이 2,5-디메톡시페닐그룹인 방법.
  7. 제 1 항에 있어서, R1이 메틸그룹이고, R2가 디메틸아미노그룹이며, Ar이 2,5-디메톡시페닐그룹인 방법.
  8. 유효량이 일반식(1)의 캘콘유도체 도는 그의 약제학적으로 허용되는 염을 투여함을 특징으로 하여, 그를 필요로 하는 환자에 있어서 종양조직의 증식을 억제하는 방법
    상기 식에서, Ar은 2,5-디메톡시페닐, 2,3,4-트리메톡시페닐, 또는 3,4,5-트리메톡시페닐그룹이고 ; R1은 수소, (C1-C4)알킬, 클로로 또는 브로모그룹이며 ; R2는 -N(R)2또는 -NH(O)R (여기서, R은 (C1-C4)알킬그룹이다)이다.
  9. 제 8 항에 있어서, R1이 (C1-C4)알킬그룹인 방법.
  10. 제 8 항에 있어서, R1이 메틸그룹인 방법.
  11. 제8,9 또는 10항에 있어서, R2가 -N(R)2인 방법.
  12. 제11항에 있어서, R이 메틸그룹인 방법.
  13. 제 8 항 내지 제12항중 어느 한 항에 있어서, Ar이 2,5-디메톡시페닐그룹인 방법.
  14. 제 8 항에 있어서, R1이 메틸그룹이고, R2가 디메틸아미노그룹이며, Ar이 2,5-디메톡시페닐그룹인 방법.
    ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019880003946A 1987-04-09 1988-04-08 캘콘 유도체를 사용한 종량 조직의 증식 억제방법 KR880012217A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US036227 1987-04-09
US07/036,227 US4904697A (en) 1987-04-09 1987-04-09 Controlling the growth of certain tumor tissue with chalcone derivatives

Publications (1)

Publication Number Publication Date
KR880012217A true KR880012217A (ko) 1988-11-26

Family

ID=21887400

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880003946A KR880012217A (ko) 1987-04-09 1988-04-08 캘콘 유도체를 사용한 종량 조직의 증식 억제방법

Country Status (8)

Country Link
US (1) US4904697A (ko)
EP (1) EP0288794B1 (ko)
KR (1) KR880012217A (ko)
AT (1) ATE106723T1 (ko)
AU (1) AU599220B2 (ko)
DE (1) DE3889970T2 (ko)
PH (1) PH25183A (ko)
ZA (1) ZA882391B (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives
AU634921B2 (en) * 1990-12-25 1993-03-04 Ohgen Research Laboratories Ltd. Deacetylcolchicine derivatives
AU2776892A (en) * 1991-10-07 1993-05-03 Cancer Immunology Research Corporation, The Treatment of premalignant and malignant lesions
US5681812A (en) * 1991-12-10 1997-10-28 Rush Presbyterian-St. Luke's Medical Center Methods and compositions for reducing multidrug resistance
AU3243393A (en) * 1991-12-10 1993-07-19 Rush - Presbyterian - St. Luke's Medical Center Methods and compositions for reducing multi-drug resistance
US5952355A (en) * 1993-11-17 1999-09-14 Kyowa Hakko Kogyo Co., Ltd. Propenone derivatives
IL112205A0 (en) * 1994-01-06 1995-03-15 Res Dev Foundation Curcumin, analogues of curcumin and novel uses thereof
GB9401891D0 (en) * 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
US5834442A (en) * 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
EP0770601A4 (en) * 1995-05-10 1998-08-05 Kyowa Hakko Kogyo Kk PROPENONE DERIVATIVES
IL121789A (en) * 1996-10-03 2001-06-14 Rohm & Haas A medicinal product for inhibiting mammalian cell tumors
US20030157187A1 (en) * 1996-12-02 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
AU771994B2 (en) * 1996-12-02 2004-04-08 Ipxmedical, Llc Compositions and methods for treating or preventing inflammatory diseases
AU2004200715B2 (en) * 1996-12-02 2006-08-31 Angiotech International Ag Compositions and methods for treating or preventing inflammatory diseases
US6515016B2 (en) * 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
EP0947511A1 (en) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and of phenoxymethyl tetrazole having antitumor activity
EP0947494A1 (en) * 1998-03-30 1999-10-06 F. Hoffmann-La Roche Ag Derivatives of phenoxy acetic acid and phenoxymethyltetrazole having antitumor activity
CN1447804A (zh) 2000-06-20 2003-10-08 阿特罗吉尼克斯公司 1,3－二－(被取代的苯基)－2－丙烯－1－酮及其治疗vcam－1介导的疾病的用途
BR0115474A (pt) 2000-11-17 2006-01-31 Idenix Cayman Ltd Composição e método para inibição da transmissão de hiv que usam 6-benzil-4-oxopirimidinas substituìdas aplicada por via tópica
FR2817749A1 (fr) * 2000-12-13 2002-06-14 Aventis Pharma Sa Nouvelle utilisation des composes de la classe des chalcones
GB0126889D0 (en) * 2001-11-08 2002-01-02 Paterson Inst For Cancer Res Compounds and their uses
PE20030758A1 (es) * 2001-12-05 2003-10-07 Aventis Pharma Sa 1,3-diarilprop-2-en-1-onas, composiciones que las contienen y su utilizacion
US20040147584A2 (en) * 2001-12-05 2004-07-29 Aventis Pharma S.A. 1,3-diarylprop-2-en-1-ones, compositions containing them and use thereof
FR2833008B1 (fr) * 2001-12-05 2004-05-21 Aventis Pharma Sa 1,3-diarylprop-2-en-1-ones, compositions les contenant et utilisation
FR2833004B1 (fr) * 2001-12-05 2004-12-10 Aventis Pharma Sa Aryl-cycloalcaines substitues, compositions les contenant et utilisation
TW200303302A (en) * 2001-12-19 2003-09-01 Atherogenics Inc Chalcone derivatives and their use to treat diseases
AU2002342808A1 (en) * 2002-10-09 2004-05-04 Unibioscreen S.A. Extract with anti-tumor and anti-poisonous activity
WO2004056727A2 (en) * 2002-12-19 2004-07-08 Atherogenics, Inc. Process of making chalcone derivatives
US7326734B2 (en) * 2003-04-01 2008-02-05 The Regents Of The University Of California Treatment of bladder and urinary tract cancers
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
EP3200794A4 (en) 2014-09-29 2018-06-20 The Penn State Research Foundation A compound for anti-cancer therapy that acts by targeting gof mutant p53 and stimulates p73
US11746104B2 (en) 2019-06-13 2023-09-05 Qatar University Chalcone-based chemotherapeutic compound for triple negative breast cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL255071A (ko) * 1959-08-20
US3729313A (en) * 1971-12-06 1973-04-24 Minnesota Mining & Mfg Novel photosensitive systems comprising diaryliodonium compounds and their use
US3808006A (en) * 1971-12-06 1974-04-30 Minnesota Mining & Mfg Photosensitive material containing a diaryliodium compound, a sensitizer and a color former
DE2602419A1 (de) * 1976-01-23 1977-07-28 Basf Ag Photopolymerisierbare masse
JPS6026122B2 (ja) * 1977-01-20 1985-06-21 富士写真フイルム株式会社 光重合性組成物
US4162162A (en) * 1978-05-08 1979-07-24 E. I. Du Pont De Nemours And Company Derivatives of aryl ketones and p-dialkyl-aminoarylaldehydes as visible sensitizers of photopolymerizable compositions
JPS54152091A (en) * 1978-05-22 1979-11-29 Fuji Photo Film Co Ltd Photopolymerizable composition
US4279930A (en) * 1978-10-10 1981-07-21 The Upjohn Company Process for treating inflammation
NZ192641A (en) * 1979-01-26 1984-10-19 Hoffmann La Roche Substituted acetophenones and pharmaceutical compositions
EP0028305B1 (en) * 1979-09-13 1984-02-01 The Wellcome Foundation Limited Diaryl compounds and pharmaceutical formulations containing them
CA1168659A (fr) * 1980-08-06 1984-06-05 Gerard Lang Derives de dibenzoylmethane quaternaire, leur utilisation comme agent filtrant solaire et composition cosmetique les contenant
US4753965A (en) * 1987-04-09 1988-06-28 Merrell Dow Pharmaceuticals, Inc. Method of treating multiple sclerosis with chalcone derivatives

Also Published As

Publication number Publication date
EP0288794A2 (en) 1988-11-02
PH25183A (en) 1991-03-27
ATE106723T1 (de) 1994-06-15
US4904697A (en) 1990-02-27
DE3889970D1 (de) 1994-07-14
ZA882391B (en) 1988-09-23
EP0288794B1 (en) 1994-06-08
AU1416488A (en) 1988-10-13
EP0288794A3 (en) 1988-11-23
AU599220B2 (en) 1990-07-12
DE3889970T2 (de) 1994-10-06

Similar Documents

Publication Publication Date Title
KR880012217A (ko) 캘콘 유도체를 사용한 종량 조직의 증식 억제방법
KR880012218A (ko) 캘폰 유도체를 사용한 다발성 경화증의 치료방법
ES2075202T3 (es) Nuevas arilpiridazinas, su preparacion, su utilizacion, y medicamentos que las contienen.
KR950016732A (ko) 피부 및 질의 위축 억제방법
DE3671370D1 (de) Zubereitungen zur behandlung von mycoplasmosen und bakteriellen erkrankungen bei gefluegel.
ATE418975T1 (de) Pharmazeutische zubereitungen zur behandlung von hemoglobulinopathien der beta-chain
KR950010892A (ko) 자궁 섬유증 억제 방법
MX9204622A (es) Nuevos derivados de 3,5-di-tert-butil-4-hidroxifenilo, procedimiento para su preparacion y composicion farmaceutica que los contiene.
KR950010891A (ko) 내성 종양을 치료하는 방법
KR950016726A (ko) 기능부전성 자궁 출혈을 억제하는 방법
KR940005274A (ko) 쇼그렌(Sjoegren)증후군 치료제
KR950010887A (ko) 연골 퇴화 억제 방법
ES2060173T3 (es) Derivados de lisolecitina para el tratamiento de enfermedades autoinmunologicas.
DE69428325T2 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung der Angiogenese und angiogene Krankheiten
DE69201660T2 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
FI934680A (fi) Arylmorfolin, framstaellning och anvaending
KR950016741A (ko) 체중 증가를 억제하거나 또는 체중 감소를 유도하는 방법
KR950013508A (ko) 수면 장애의 치료에 유용한 멜라토닌 유도체
DE68906965D1 (de) Analgetische phenothiazinderivate.
KR920017668A (ko) 암 전이 억제 또는 예방 방법 및 이를 위한 제제
ATE18761T1 (de) Carbamoyloxybenzhydrol-derivate, ihre herstellung und ihre pharmazeutische zusammensetzungen.
KR900701262A (ko) 췌장염 등에 대한 치료제
KR890003372A (ko) 피리미도[2,1-b] 벤조티아졸 유도체로된 동맥경화 치료의약
ATE162516T1 (de) Nichtmetabolisierbare clomiphene-analoge zur behandlung von tamoxifen-resistenten tumoren
KR950016728A (ko) 여성에서 다모증 및 탈모증을 억제하는 방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid